ASTELLAS-1707-CL-0011

Study Sponsor: Astellas

Study Title

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment

Medicine or Vaccine (generic name)

ASP1707

Sponsor Identification Number

1707-CL-0011

Trial Registry Identification Number(#'s)

NCT01767090
EudraCT 2012-002791-14

Medical Condition

Endometriosis

Phase

Phase 2

Link to Astellas Study Register

https://www.clinicaltrials.astellas.com/study/1707-CL-0011

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT01767090

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002791-14

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

February 2020